LONDON – Shield Therapeutics plc has pulled back from the brink after the FDA weighed up a revised analysis of its phase III trial of the iron replacement therapy Feraccru in patients with chronic kidney disease (CKD), and told the company it does not need to conduct further trials before submitting a new drug application (NDA).